CN105535978A - Tumor stem cell optional killing agent and application thereof - Google Patents

Tumor stem cell optional killing agent and application thereof Download PDF

Info

Publication number
CN105535978A
CN105535978A CN201610077128.7A CN201610077128A CN105535978A CN 105535978 A CN105535978 A CN 105535978A CN 201610077128 A CN201610077128 A CN 201610077128A CN 105535978 A CN105535978 A CN 105535978A
Authority
CN
China
Prior art keywords
iridoid
parts
stem cell
tumor stem
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610077128.7A
Other languages
Chinese (zh)
Inventor
寇卫政
杨留中
杨庆辉
王颖
蔡卫梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of Xinxiang Medical University
Original Assignee
First Affiliated Hospital of Xinxiang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of Xinxiang Medical University filed Critical First Affiliated Hospital of Xinxiang Medical University
Priority to CN201610077128.7A priority Critical patent/CN105535978A/en
Publication of CN105535978A publication Critical patent/CN105535978A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae

Abstract

The invention discloses a tumor stem cell optional killing agent and application thereof. The optional killing agent is prepared from the following raw materials in parts by weight: 10-20 parts of copper-doped nano-gold powder, 10-15 parts of quinazoline alkaloid compound, 10-20 parts of polyphenol flavone compound, 10-20 parts of iridoid glycoside compound, 10-15 parts of isocorydine, 1-5 parts of oleuropein, 3-5 parts of arsenic trioxide and 10-20 parts of common nostoc extract. According to the tumor stem cell optional killing agent, multiple effective ingredients are coupled to the copper-doped nano-gold powder, and are transformed into small-sized gold quantum dots of 2-5nm under the high-power ultrasonic effect, so that the killing agent can be used for optionally killing tumor cells and hardly has toxic or side effect, and the immunity of patients can be improved.

Description

A kind of tumor stem cell selective killing agent and application thereof
Technical field
The present invention relates to therapeutic field of tumor, be specifically related to the agent of a kind of tumor stem cell selective killing and application thereof.
Background technology
Tumor is one of major disease affecting human health, is also the maximum difficult medical problem that world medical circle faces, and the growth of tumour cell inhibitor finding to have an excellent activity is badly in need of by medical science and pharmaceutical field.
At present, modern medicine is to the treatment of tumor mainly operative treatment cooperation Radiotherapy chemotherapy, and part adopts targeting or genomic medicine simultaneously, is equipped with response Chinese traditional treatment and improves curative effect; For local or infantile tumour, considerable part adopts laser or focus ultrasonic or alternation magnetic resonance thermotherapy treatment partial malignancy, or local operation.Though local operation can remove most of primary lesion, regeneration and the breeding of cancerous cell fundamentally can not be stopped; Though Radiotherapy chemotherapy can kill cancerous cell, but also make to comprise normal immunological histiocyte in a large number to suffer damage simultaneously, bring out bad gastrointestinal reaction, bone marrow depression and Liver and kidney, impairment of cardiac function, make the health of patient weaker, resist the disease and anti-infection ability significantly reduce, and most trouble carninomatosis people is difficult to realize successful treatment or extend life cycle.
Summary of the invention
For solving the problem, the invention provides the agent of a kind of tumor stem cell selective killing and application thereof.
For achieving the above object, the technical scheme that the present invention takes is:
The agent of a kind of tumor stem cell selective killing, is prepared from by the raw material of following weight portion:
Jenner's rice flour 10-20 part of copper doped, quinazoline alkaloid compound 10-15 part, polyphenol chromocor compounds 10-20 part, iridoid glycoside compounds 10-20 part, isocorydine 10-15 part, oleuropein 1-5 part, arsenic trioxide 3-5 part, nostoc sphaeroids kutz extractive 10-20 part.
Preferably, described in, the quality doping of the copper of Jenner's rice flour of copper doped is 0.3%-0.7%.
Preferably, described iridoid glycoside compounds is that iridoid list glycosides oleoside methyl ester, iridoid list glycosides oil glycoside are to one or more the mixture in hydroxy methacrylate, iridoid two glycosides oil glycoside glucose ester, hydroxyl iridoid list glycosides oleoside methyl ester, iridoid tri-glucose glycosides, the two glucoside of iridoid.
Preferably, the molecular formula of described quinazoline alkaloid compound is C 26h 25n 5o 4.
Above-mentioned selective killing agent can be used for inducing apoptosis of tumour cell or is used as apoptosis of tumor cells derivant or promoter.
The present invention has following beneficial effect:
Plurality of active ingredients is coupled on Jenner's rice flour of copper doped, then by high-power ultrasonication, 2-5nm small size gold quantum dot can be converted into, and then selective killing tumor cell and to normal this nonhazardous of cell based effect, improve patient's immunocompetence.
Detailed description of the invention
In order to make objects and advantages of the present invention clearly understand, below in conjunction with embodiment, the present invention is further elaborated.Should be appreciated that specific embodiment described herein only in order to explain the present invention, be not intended to limit the present invention.
Embodiment 1
The agent of a kind of tumor stem cell selective killing, is prepared from by the raw material of following weight portion:
10 parts, Jenner's rice flour of copper doped, quinazoline alkaloid compound 10 parts, polyphenol chromocor compounds 10 parts, iridoid glycoside compounds 10 parts, isocorydine 10 parts, oleuropein 1 part, arsenic trioxide 3 parts, nostoc sphaeroids kutz extractive 10 parts, the quality doping of the copper of Jenner's rice flour of described copper doped is 0.3%.Described iridoid glycoside compounds is that iridoid list glycosides oleoside methyl ester, iridoid list glycosides oil glycoside are to one or more the mixture in hydroxy methacrylate, iridoid two glycosides oil glycoside glucose ester, hydroxyl iridoid list glycosides oleoside methyl ester, iridoid tri-glucose glycosides, the two glucoside of iridoid.The molecular formula of described quinazoline alkaloid compound is C 26h 25n 5o 4.
Embodiment 2
The agent of a kind of tumor stem cell selective killing, is prepared from by the raw material of following weight portion:
20 parts, Jenner's rice flour of copper doped, quinazoline alkaloid compound 15 parts, polyphenol chromocor compounds 20 parts, iridoid glycoside compounds 20 parts, isocorydine 15 parts, oleuropein 5 parts, arsenic trioxide 5 parts, nostoc sphaeroids kutz extractive 20 parts, the quality doping of the copper of Jenner's rice flour of described copper doped is 0.7%.Described iridoid glycoside compounds is that iridoid list glycosides oleoside methyl ester, iridoid list glycosides oil glycoside are to one or more the mixture in hydroxy methacrylate, iridoid two glycosides oil glycoside glucose ester, hydroxyl iridoid list glycosides oleoside methyl ester, iridoid tri-glucose glycosides, the two glucoside of iridoid.The molecular formula of described quinazoline alkaloid compound is C 26h 25n 5o 4.
Embodiment 3
The agent of a kind of tumor stem cell selective killing, is prepared from by the raw material of following weight portion:
15 parts, Jenner's rice flour of copper doped, quinazoline alkaloid compound 12.5 parts, polyphenol chromocor compounds 15 parts, iridoid glycoside compounds 15 parts, isocorydine 12.5 parts, oleuropein 3 parts, arsenic trioxide 4 parts, nostoc sphaeroids kutz extractive 15 parts, the quality doping of the copper of Jenner's rice flour of described copper doped is 0.5%.Described iridoid glycoside compounds is that iridoid list glycosides oleoside methyl ester, iridoid list glycosides oil glycoside are to one or more the mixture in hydroxy methacrylate, iridoid two glycosides oil glycoside glucose ester, hydroxyl iridoid list glycosides oleoside methyl ester, iridoid tri-glucose glycosides, the two glucoside of iridoid.The molecular formula of described quinazoline alkaloid compound is C 26h 25n 5o 4.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.

Claims (5)

1. the agent of tumor stem cell selective killing, is characterized in that, is prepared from by the raw material of following weight portion:
Jenner's rice flour 10-20 part of copper doped, quinazoline alkaloid compound 10-15 part, polyphenol chromocor compounds 10-20 part, iridoid glycoside compounds 10-20 part, isocorydine 10-15 part, oleuropein 1-5 part, arsenic trioxide 3-5 part, nostoc sphaeroids kutz extractive 10-20 part.
2. a kind of tumor stem cell selective killing as claimed in claim 1 agent, is characterized in that, described in, the quality doping of the copper of Jenner's rice flour of copper doped is 0.3%-0.7%.
3. a kind of tumor stem cell selective killing as claimed in claim 1 agent, it is characterized in that, described iridoid glycoside compounds is that iridoid list glycosides oleoside methyl ester, iridoid list glycosides oil glycoside are to one or more the mixture in hydroxy methacrylate, iridoid two glycosides oil glycoside glucose ester, hydroxyl iridoid list glycosides oleoside methyl ester, iridoid tri-glucose glycosides, the two glucoside of iridoid.
4. a kind of tumor stem cell selective killing as claimed in claim 1 agent, is characterized in that, the molecular formula of described quinazoline alkaloid compound is C 26h 25n 5o 4.
5. the application of a kind of tumor stem cell selective killing as claimed in claim 1 agent, is characterized in that, for inducing apoptosis of tumour cell or as apoptosis of tumor cells derivant or promoter.
CN201610077128.7A 2016-01-30 2016-01-30 Tumor stem cell optional killing agent and application thereof Pending CN105535978A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610077128.7A CN105535978A (en) 2016-01-30 2016-01-30 Tumor stem cell optional killing agent and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610077128.7A CN105535978A (en) 2016-01-30 2016-01-30 Tumor stem cell optional killing agent and application thereof

Publications (1)

Publication Number Publication Date
CN105535978A true CN105535978A (en) 2016-05-04

Family

ID=55815851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610077128.7A Pending CN105535978A (en) 2016-01-30 2016-01-30 Tumor stem cell optional killing agent and application thereof

Country Status (1)

Country Link
CN (1) CN105535978A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101444500A (en) * 2008-12-25 2009-06-03 中国人民解放军第二军医大学 Application of iridoid in preparing anti-tumor medicine
CN102657653A (en) * 2012-03-28 2012-09-12 上海市肿瘤研究所 Agent for selectively killing tumor stem cells and use thereof
US20120259205A1 (en) * 2002-02-14 2012-10-11 Peyman Gholam A Method and composition for hyperthermally treating cells
CN103570744A (en) * 2013-04-07 2014-02-12 中国海洋大学 Quinazoline alkaloid compound, preparation method thereof and application of quinazoline alkaloid compound as tumor cell growth inhibitor
CN103655613A (en) * 2013-02-08 2014-03-26 复旦大学附属肿瘤医院 Application of arsenic trioxide and water-soluble object thereof in preparing medicine for treating pancreatic cancer
CN104623660A (en) * 2015-01-21 2015-05-20 广州珂纳偲生物技术有限公司 Application of copper-doped gold nanorods in preparation of antitumor drugs
CN105017357A (en) * 2015-08-05 2015-11-04 沈阳药科大学 Polyphenol flavonoid and preparing method and application of polyphenol flavonoid

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120259205A1 (en) * 2002-02-14 2012-10-11 Peyman Gholam A Method and composition for hyperthermally treating cells
CN101444500A (en) * 2008-12-25 2009-06-03 中国人民解放军第二军医大学 Application of iridoid in preparing anti-tumor medicine
CN102657653A (en) * 2012-03-28 2012-09-12 上海市肿瘤研究所 Agent for selectively killing tumor stem cells and use thereof
CN103655613A (en) * 2013-02-08 2014-03-26 复旦大学附属肿瘤医院 Application of arsenic trioxide and water-soluble object thereof in preparing medicine for treating pancreatic cancer
CN103570744A (en) * 2013-04-07 2014-02-12 中国海洋大学 Quinazoline alkaloid compound, preparation method thereof and application of quinazoline alkaloid compound as tumor cell growth inhibitor
CN104623660A (en) * 2015-01-21 2015-05-20 广州珂纳偲生物技术有限公司 Application of copper-doped gold nanorods in preparation of antitumor drugs
CN105017357A (en) * 2015-08-05 2015-11-04 沈阳药科大学 Polyphenol flavonoid and preparing method and application of polyphenol flavonoid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
朱建贵 等: "《实用延寿中药学》", 31 October 1990, 北京出版社 *
莫开菊，谢笔钧，龚晨睿: "葛仙米多糖体内抑瘤及对免疫的影响", 《食品科学》 *
黄丽红: "橄榄苦苷的抗结肠癌作用机制", 《中外普通外科学文献（电子版）》 *

Similar Documents

Publication Publication Date Title
US6811788B2 (en) Combinations and methods for treating neoplasms
US7927612B2 (en) Combinations and methods for treating neoplasms
Spugnini et al. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report
CN103570694B (en) Preparation of icaritin and derivatives thereof and application of icaritin and derivatives of icaritin in tumor treatment
Gupta et al. Therapies in cancer treatment: An overview
KR102227117B1 (en) Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Breast Cancer
CN105106959B (en) Application and a kind of pharmaceutical composition of the cordycepin in the drug of preparation and radiotherapy and/or chemotherapy synergistic treatment tumour
CN1447689A (en) Radioprotective agents
WO1992014454A1 (en) Use of quinones in the treatment of cancer or aids
US20110250292A1 (en) Composition for improving radiotherapy for cancer
JP6444515B2 (en) Application of taurine in the prevention and / or treatment of diseases caused by coronavirus and / or rotavirus viruses
CN105535978A (en) Tumor stem cell optional killing agent and application thereof
US6147086A (en) Method employing imiquimod cream for treatment of topical sarcoidosis on equine
CN104800204A (en) Morusin anti-tumor application
CN100435808C (en) Chinese medicine for treating dermatosis and tumor
CN103656646A (en) Anti-tumor drug composition and application thereof
CN111632146B (en) Application of OAT inhibitor and oncolytic virus in preparation of antitumor drugs
CN1287796C (en) Composition of epigallocatechin, gallate and folic acid and its use
CN108309969A (en) Medical application of the tectorigenin in treating chicken necrotizing enterocolitis
KR102437311B1 (en) A pharmaceutical composition comprising NDPK activator and SGLT-2 inhibitor for treating cancer)
CN101966192A (en) Application of orsythoside A in preparation of medicament for treating herpes simplex
EA004603B1 (en) Method for preventing and treating diseases of an immune system and a remedy for carrying out said method
KR102079844B1 (en) Pharmaceutical composition for treating gallbladder disease, comprising a gallstone dissolving agent
Toshkova et al. A plant extract ameliorates the disfunctions of alveolar macrophages in influenza virus-infected mice
CN104306972B (en) The novel photosensitive agent of a kind of photodynamic therapy anti-malignant tumor and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160504